DAFNA Capital Management’s Larimar Therapeutics LRMR Stock Holding History

DAFNA Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.12M	Sell	2,008,164 -21,000	-1%	-$83.4K	1.17%	21
2026 Q1	$9.13M	Buy	2,029,164 +1,090,000	+116%	+$4.36M	2.08%	14
2025 Q4	$3.58M	Sell	939,164 -88,600	-9%	-$345K	0.83%	32
2025 Q3	$3.32M	Buy	1,027,764 +656,330	+177%	+$2.46M	0.82%	31
2025 Q2	$1.07M	Hold	371,434	–	–	0.3%	55
2025 Q1	$799K	Hold	371,434	–	–	0.23%	65
2024 Q4	$1.44M	Sell	371,434 -122,840	-25%	-$811K	0.37%	48
2024 Q3	$3.24M	Sell	494,274 -145,700	-23%	-$1.17M	0.76%	32
2024 Q2	$4.64M	Sell	639,974 -16,399	-2%	-$126K	1.11%	25
2024 Q1	$4.98M	Buy	656,373 +332,500	+103%	+$2.59M	1.13%	27
2023 Q4	$1.47M	Sell	323,873 -3,500	-1%	-$11.8K	0.35%	51
2023 Q3	$1.29M	Sell	327,373 -23,000	-7%	-$87K	0.4%	47
2023 Q2	$1.1M	Buy	350,373 +113,500	+48%	+$463K	0.3%	51
2023 Q1	$1.07M	Sell	236,873 -236,263	-50%	-$1.23M	0.32%	45
2022 Q4	$1.95M	Sell	473,136 -101,860	-18%	-$348K	0.55%	46
2022 Q3	$1.84M	Buy	574,996 +525,000	+1,050%	+$1.32M	0.49%	43
2022 Q2	$98K	Hold	49,996	–	–	0.03%	90
2022 Q1	$202K	Sell	49,996 -20,181	-29%	-$132K	0.05%	91
2021 Q4	$757K	Buy	70,177 +5,690	+9%	+$63.3K	0.19%	72
2021 Q3	$744K	Sell	64,487 -12,500	-16%	-$150K	0.2%	72
2021 Q2	$756K	Sell	76,987 -4,445	-5%	-$50.2K	0.16%	76
2021 Q1	$1.19M	Buy	81,432 +33,004	+68%	+$600K	0.28%	70
2020 Q4	$1.04M	Sell	48,428 -30,727	-39%	-$616K	0.31%	59
2020 Q3	$1.2M	Sell	79,155 -47,106	-37%	-$596K	0.39%	51
2020 Q2	$1.62M	Buy	126,261 +100,803	+396%	+$1.17M	0.47%	44
2020 Q1	$235K	Hold	25,458	–	–	0.1%	76
2019 Q4	$339K	Hold	25,458	–	–	0.12%	74
2019 Q3	$226K	Buy	25,458 +1,666	+7%	+$18.3K	0.09%	81
2019 Q2	$340K	Sell	23,792 -3,875	-14%	-$103K	0.13%	77
2019 Q1	$910K	Buy	27,667 +21,644	+359%	+$1.11M	0.39%	53
2018 Q4	$358K	Sell	6,023 -1,131	-16%	-$112K	0.18%	63
2018 Q3	$1M	Sell	7,154 -6,461	-47%	-$784K	0.41%	52
2018 Q2	$1.67M	Buy	+13,615	New	+$1.16M	0.78%	36

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

DAFNA Capital Management's LRMR Position: Q2 2026 in Review

DAFNA Capital Management reduced its Larimar Therapeutics (LRMR) stake by 1% in Q2 2026, selling an estimated $83.4K and leaving 2,008,164 shares worth $6.12M. The position accounts for 1.17% of the portfolio, ranked #21.

DAFNA Capital Management first reported a position in LRMR in Q2 2018 and has held it in 33 quarters since. The position peaked at $9.13M in Q1 2026. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

DAFNA Capital Management held 2,008,164 shares of Larimar Therapeutics worth $6.12M as of Q2 2026.
DAFNA Capital Management sold 21,000 Larimar Therapeutics shares in Q2 2026, an estimated $83.4K.
Larimar Therapeutics made up 1.17% of DAFNA Capital Management's portfolio in Q2 2026, its #21 holding.
DAFNA Capital Management first reported a position in Larimar Therapeutics in Q2 2018 and has held it in 33 quarters since.
DAFNA Capital Management's Larimar Therapeutics position peaked at $9.13M in Q1 2026.
163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.